Artificial Intelligence-based Clinical Trial Solutions for Patient Matching

A Global Strategic Business Report

MCP29240

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7148

EXECUTIVE POOL

5850

PRICE

817

EXPERT INPUTS

36

COMPANIES

76

DATA TABLES

142

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market to Reach US$2.4 Billion by 2030

The global market for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching estimated at US$641.6 Million in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 24.8% over the analysis period 2024-2030. Oncology Application, one of the segments analyzed in the report, is expected to record a 25.3% CAGR and reach US$648.9 Million by the end of the analysis period. Growth in the Metabolic Diseases Application segment is estimated at 24.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.7 Million While China is Forecast to Grow at 23.5% CAGR

The Artificial Intelligence-based Clinical Trial Solutions for Patient Matching market in the U.S. is estimated at US$168.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$369.2 Million by the year 2030 trailing a CAGR of 23.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 22.7% and 21.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR.

Global Artificial Intelligence-Based Clinical Trial Solutions for Patient Matching Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing Patient Matching in Clinical Trials?

Artificial Intelligence (AI) is transforming patient matching in clinical trials by significantly improving the speed, accuracy, and efficiency of participant identification. Traditional methods of recruiting patients for clinical trials are often time-consuming and rely on manual processes that are prone to errors and delays. AI-based solutions leverage advanced machine learning algorithms to analyze vast amounts of patient data from electronic health records (EHRs), genetic databases, and medical histories. These algorithms identify eligible participants who meet the specific criteria for trials, ensuring a more targeted and effective recruitment process.

AI’s ability to process unstructured data, such as physician notes and imaging results, is another game-changer in patient matching. By extracting relevant information and cross-referencing it with trial requirements, AI systems can uncover candidates who might otherwise be overlooked. Furthermore, AI enables dynamic updates to patient eligibility as trial protocols evolve, ensuring a consistent and optimized recruitment process. This efficiency reduces trial delays and enhances the likelihood of success, making AI indispensable in the clinical trial ecosystem.

What Drives the Adoption of AI in Clinical Trial Patient Matching?

The increasing complexity of clinical trials and the growing demand for personalized medicine are driving the adoption of AI-based solutions in patient matching. As precision medicine gains traction, trials require participants with highly specific genetic, demographic, and clinical profiles. AI excels at sifting through large datasets to identify individuals who meet these precise criteria, addressing a critical challenge in modern clinical research. This capability is especially valuable for rare disease trials, where finding eligible participants can be particularly difficult.

Additionally, the rising cost and duration of clinical trials are prompting pharmaceutical companies to adopt AI-driven solutions to improve efficiency. Patient recruitment is a major bottleneck in the trial process, and delays in this phase can lead to significant financial losses. AI streamlines this process, reducing recruitment timelines and enabling trials to proceed faster. Regulatory support for the use of AI in healthcare, combined with advancements in data interoperability, is further boosting the adoption of these technologies. These factors collectively highlight the growing importance of AI in addressing the challenges of patient matching in clinical trials.

Can AI Improve Equity and Accessibility in Clinical Trials?

AI-based clinical trial solutions are playing a pivotal role in enhancing equity and accessibility in clinical research. Historically, underrepresentation of certain demographic groups in clinical trials has been a significant issue, leading to biased outcomes and limiting the generalizability of findings. AI can address this challenge by identifying diverse patient populations that align with trial eligibility criteria, ensuring broader representation. By analyzing socio-demographic data alongside clinical information, AI systems can facilitate more inclusive recruitment processes that reflect the diversity of real-world patient populations.

Moreover, AI-based platforms enable remote and decentralized trial models, expanding access to participants in underserved and geographically remote areas. These platforms leverage telehealth and mobile health solutions to engage patients, reducing the need for frequent travel to trial sites. This is particularly beneficial for individuals with limited mobility or access to specialized healthcare facilities. By bridging these gaps, AI is democratizing participation in clinical trials, fostering inclusivity and ensuring that the benefits of medical research are more widely distributed.

What’s Driving the Growth of the AI-Based Clinical Trial Solutions Market?

The growth in the Artificial Intelligence-Based Clinical Trial Solutions for Patient Matching market is driven by several critical factors, reflecting the increasing reliance on AI to overcome the challenges of clinical research. The escalating complexity of trial designs, coupled with the growing prevalence of chronic and rare diseases, is fueling demand for AI solutions that streamline patient recruitment. AI’s ability to enhance trial efficiency and reduce costs is also attracting significant investments from pharmaceutical companies and contract research organizations (CROs).

Advancements in data integration technologies and the increasing availability of large, high-quality healthcare datasets are further enabling the adoption of AI-driven tools. Consumer behavior trends, such as the increasing use of wearable health devices and patient portals, are generating valuable real-time data that can be leveraged for patient matching. Regulatory initiatives aimed at fostering innovation in clinical research are also supporting the growth of AI-based solutions. These factors, combined with continuous advancements in AI algorithms and cloud computing, are driving the market’s rapid expansion and positioning AI as a cornerstone in the future of clinical trials.

SCOPE OF STUDY

The report analyzes the Artificial Intelligence-based Clinical Trial Solutions for Patient Matching market by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application, Other Applications); End-Use (Pharmaceutical Companies End-Use, Academia End-Use, Other End-Uses).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

AmerisourceBergen Corporation; Antidote.me; ArisGlobal LLC; ConcertAI LLC; Deep 6 AI, Inc.; Mendel.ai; Microsoft Corporation; Paradigm Health, Inc.; Persistent Systems Ltd.; Unlearn.Ai, Inc.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Economic Frontiers: Trends, Trials & Transformations

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 36 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

AI-Powered Solutions Drive Market Growth by Improving Patient Recruitment Efficiency

Real-Time Data Integration in AI Platforms Expands Market Opportunities for CROs (Contract Research Organizations)

AI Solutions Spur Adoption for Diverse Patient Inclusion in Global Clinical Trials

Drug Development Pipelines Bode Well for Growth of AI in Accelerating Trial Timelines

AI-Driven Predictive Models Minimize Attrition Rates, Enhancing Trial Success

Demand for Cost Optimization Fuels AI Adoption in Clinical Trial Design

AI in Remote Monitoring of Trial Participants Creates New Opportunities for Decentralized Trials

AI Solutions for Early Disease Detection Propel Market Growth in Rare Disease Trials

AI in Mobile Health Devices Highlights Opportunities for Seamless Patient Data Collection

Big Pharma Embraces AI in Trial Feasibility Studies to Improve ROI

4. GLOBAL MARKET PERSPECTIVE

World Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Metabolic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Metabolic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Neurological Diseases or Conditions Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Neurological Diseases or Conditions Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Academia End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Academia End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

USA Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Canada Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

JAPAN

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Japan Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

CHINA

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

China Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

EUROPE

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030

Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

FRANCE

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

France Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

GERMANY

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Germany Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Italy Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

UNITED KINGDOM

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

UK Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

ASIA-PACIFIC

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
AmerisourceBergen Corporation	%
Antidote.me	%
ArisGlobal LLC	%
ConcertAI LLC	%
Deep 6 AI, Inc.	%
Mendel.ai	%
Microsoft Corporation	%
Paradigm Health, Inc.	%
Unlearn.Ai, Inc.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll